These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 32723974)

  • 21. Exploration of Novel Immunological Terms in Lung Cancer With Large Populations: Implications for Immunotherapy.
    Yao Y; Wang J; Yang F; Gao W
    Front Immunol; 2022; 13():924498. PubMed ID: 35844536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA hypermethylation of microRNA-34b/c has prognostic value for stage Ⅰ non-small cell lung cancer.
    Wang Z; Chen Z; Gao Y; Li N; Li B; Tan F; Tan X; Lu N; Sun Y; Sun J; Sun N; He J
    Cancer Biol Ther; 2011 Mar; 11(5):490-6. PubMed ID: 21383543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenome-wide gene-age interaction analysis reveals reversed effects of
    Chen C; Wei Y; Wei L; Chen J; Chen X; Dong X; He J; Lin L; Zhu Y; Huang H; You D; Lai L; Shen S; Duan W; Su L; Shafer A; Fleischer T; Bjaanæs MM; Karlsson A; Planck M; Wang R; Staaf J; Helland Å; Esteller M; Zhang R; Chen F; Christiani DC
    Aging (Albany NY); 2020 Jun; 12(11):10642-10662. PubMed ID: 32511103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
    Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
    Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gene Methylation Biomarkers in Sputum and Plasma as Predictors for Lung Cancer Recurrence.
    Belinsky SA; Leng S; Wu G; Thomas CL; Picchi MA; Lee SJ; Aisner S; Ramalingam S; Khuri FR; Karp DD
    Cancer Prev Res (Phila); 2017 Nov; 10(11):635-640. PubMed ID: 28904059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Methylated +322-327 CpG site decreases hOGG1 mRNA expression in non-small cell lung cancer.
    Zeng Y; Zhu J; Qin H; Shen D; Lei Z; Li W; Ding Z; Huang JA; Liu Z
    Oncol Rep; 2017 Jul; 38(1):529-537. PubMed ID: 28586012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Statistical and bioinformatic analysis of hemimethylation patterns in non-small cell lung cancer.
    Sun S; Zane A; Fulton C; Philipoom J
    BMC Cancer; 2021 Mar; 21(1):268. PubMed ID: 33711952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction of a 5-methylcytosine-Related Molecular Signature to Inform the Prognosis and Immunotherapy of Lung Squamous Cell Carcinoma.
    He R; Feng X; Yang K; Zhou X; Li W; Zeng J
    Expert Rev Mol Diagn; 2022 Sep; 22(9):905-913. PubMed ID: 36197838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immune response-related mutational signatures and driver genes in non-small-cell lung cancer.
    Chen H; Chong W; Teng C; Yao Y; Wang X; Li X
    Cancer Sci; 2019 Aug; 110(8):2348-2356. PubMed ID: 31222843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
    Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
    Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Machine-Learning and Stochastic Tumor Growth Models for Predicting Outcomes in Patients With Advanced Non-Small-Cell Lung Cancer.
    Siah KW; Khozin S; Wong CH; Lo AW
    JCO Clin Cancer Inform; 2019 Sep; 3():1-11. PubMed ID: 31539267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies.
    Carter CA; Zeman K; Day RM; Richard P; Oronsky A; Oronsky N; Lybeck M; Scicinski J; Oronsky B
    Oncotarget; 2016 Jun; 7(26):40781-40791. PubMed ID: 27007055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects.
    Zhang R; Chen C; Dong X; Shen S; Lai L; He J; You D; Lin L; Zhu Y; Huang H; Chen J; Wei L; Chen X; Li Y; Guo Y; Duan W; Liu L; Su L; Shafer A; Fleischer T; Moksnes Bjaanæs M; Karlsson A; Planck M; Wang R; Staaf J; Helland Å; Esteller M; Wei Y; Chen F; Christiani DC
    Chest; 2020 Aug; 158(2):808-819. PubMed ID: 32113923
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Lu J; Zhong R; Lou Y; Hu M; Yang Z; Wang Y; Chen Y; Zou B; Zhang W; Wang H; Han B
    Front Immunol; 2021; 12():732125. PubMed ID: 34603310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database.
    Singal G; Miller PG; Agarwala V; Li G; Kaushik G; Backenroth D; Gossai A; Frampton GM; Torres AZ; Lehnert EM; Bourque D; O'Connell C; Bowser B; Caron T; Baydur E; Seidl-Rathkopf K; Ivanov I; Alpha-Cobb G; Guria A; He J; Frank S; Nunnally AC; Bailey M; Jaskiw A; Feuchtbaum D; Nussbaum N; Abernethy AP; Miller VA
    JAMA; 2019 Apr; 321(14):1391-1399. PubMed ID: 30964529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
    J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The emerging development of tumor mutational burden in patients with NSCLC.
    Zhang Y; Wang L; Li R; Liu B
    Future Oncol; 2020 Mar; 16(9):469-481. PubMed ID: 32048882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
    Imperatori A; Sahnane N; Rotolo N; Franzi F; Nardecchia E; Libera L; Romualdi C; Cattoni M; Sessa F; Dominioni L; Furlan D
    Lung Cancer; 2017 Jun; 108():83-89. PubMed ID: 28625654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can aberrant promoter hypermethylation of CpG islands predict the clinical outcome of non-small cell lung cancer after curative resection?
    Kim YT; Lee SH; Sung SW; Kim JH
    Ann Thorac Surg; 2005 Apr; 79(4):1180-8; discussion 1180-8. PubMed ID: 15797047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomewide DNA methylation analysis identifies novel methylated genes in non-small-cell lung carcinomas.
    Carvalho RH; Hou J; Haberle V; Aerts J; Grosveld F; Lenhard B; Philipsen S
    J Thorac Oncol; 2013 May; 8(5):562-73. PubMed ID: 23524404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.